| 753 |
SANT-2
|
-
SANT-2, CAS-RN: 329196-48-7, DTXSID40362255
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 754 |
SANT-3
|
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 755 |
SANT-4
|
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 751 |
SANT1
|
|
None
|
| 642 |
Saracatinib
|
-
Saracatinib, CAS-RN: 379231-04-6, DTXSID90191355
|
399: Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)
|
| 526 |
SARS-CoV
|
|
3 AOPs
|
| 619 |
SARS-CoV and CoV-NL63, SARS-CoV
|
|
None
|
| 624 |
Sars-CoV-2
|
|
6 AOPs
|
| 468 |
SB-210661
|
|
297: Inhibition of retinaldehyde dehydrogenase leads to population decline
|
| 476 |
SB216763
|
|
None
|
| 426 |
SC-839
|
|
None
|
| 51 |
Selected AHR Ligands
|
|
None
|
| 295 |
serotonin transporter activation
|
|
3 AOPs
|
| 233 |
sertraline
|
-
Sertraline, CAS-RN: 79617-96-2, DTXSID6023577
|
203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
|
| 677 |
Serum
|
-
Serum, CAS-RN: NOCAS, DTXSID2041123
|
None
|
| 354 |
Sevoflurane
|
-
Sevoflurane, CAS-RN: 28523-86-6, DTXSID8046614
|
260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration
|
| 674 |
Sex hormone
|
|
None
|
| 254 |
Silica nanoparticles
|
|
2 AOPs
|
| 711 |
Silver
|
-
Silver, CAS-RN: 7440-22-4, DTXSID4024305
|
None
|
| 252 |
Silver nanoparticles
|
|
207: NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans
|
| 555 |
Simvastatin
|
-
Simvastatin, CAS-RN: 79902-63-9, DTXSID0023581
|
None
|
| 444 |
Sinefungin
|
-
Sinefungin, CAS-RN: 58944-73-3, DTXSID10207689
|
2 AOPs
|
| 305 |
Single walled carbon nanotubes
|
|
409: Frustrated phagocytosis leads to malignant mesothelioma
|
| 221 |
Small molecules: ITB3, ITB4, ITB5, ITB9
|
|
None
|
| 91 |
Sodium (4-fluoro-2-{[(1S)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide
|
|
None
|